BIOMARIN PHARMACEUTICAL INC Payments to Acquire Investments
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Payments to Acquire Investments of $25.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC payments to acquire investments for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire investments for the quarter ending 2026-03-31 was $25.79M, a 71.11% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire investments for the quarter ending 2025-12-31 was $42.61M, a 26.38% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire investments for the quarter ending 2025-09-30 was $110.83M, a 29.37% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire investments for fiscal 2025 was $355.88M, a 13.25% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC payments to acquire investments for fiscal 2024 was $410.25M, a 52.76% decline from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC payments to acquire investments for fiscal 2023 was $868.50M, a 41.96% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC payments to acquire investments for fiscal 2022 was $611.81M, a 34.72% decline from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month | Payments to Acquire Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $25.79M 10-Q · filed 2026-08-06 | $68.41M derived: sum of 3 quarters · filed 2026-08-06 | $179.23M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $25.79M 10-Q · filed 2026-05-05 | $68.41M derived: sum of 2 quarters · filed 2026-05-05 | $179.23M derived: sum of 3 quarters · filed 2026-05-05 | $292.39M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $42.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $153.44M derived: sum of 2 quarters · filed 2026-02-26 | $266.60M derived: sum of 3 quarters · filed 2026-08-06 | $355.88M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $110.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $223.99M derived: sum of 2 quarters · filed 2026-08-06 | $313.26M 10-Q · filed 2025-10-28 | $371.14M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $113.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $202.43M 10-Q · filed 2026-08-06 | $260.31M derived: sum of 3 quarters · filed 2026-08-06 | $417.22M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $89.27M 10-Q · filed 2026-05-05 | $147.15M derived: sum of 2 quarters · filed 2026-05-05 | $304.06M derived: sum of 3 quarters · filed 2026-05-05 | $377.86M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $57.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $214.79M derived: sum of 2 quarters · filed 2026-02-26 | $288.58M derived: sum of 3 quarters · filed 2026-02-26 | $410.25M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $156.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $230.71M derived: sum of 2 quarters · filed 2025-10-28 | $352.37M 10-Q · filed 2025-10-28 | $493.82M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $73.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $195.46M 10-Q · filed 2025-08-05 | $336.92M derived: sum of 3 quarters · filed 2026-02-26 | $619.91M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $121.67M 10-Q · filed 2025-05-02 | $263.12M derived: sum of 2 quarters · filed 2026-02-26 | $546.11M derived: sum of 3 quarters · filed 2026-02-26 | $769.80M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $141.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $424.45M derived: sum of 2 quarters · filed 2026-02-26 | $648.13M derived: sum of 3 quarters · filed 2026-02-26 | $868.50M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $282.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $506.68M derived: sum of 2 quarters · filed 2024-10-31 | $727.04M 10-Q · filed 2024-10-31 | $881.47M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-06-30 | $223.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $444.05M 10-Q · filed 2024-08-05 | $598.48M derived: sum of 3 quarters · filed 2025-02-24 | $751.05M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-03-31 | $220.36M 10-Q · filed 2024-04-26 | $374.79M derived: sum of 2 quarters · filed 2025-02-24 | $527.37M derived: sum of 3 quarters · filed 2025-02-24 | $684.81M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2022-12-31 | $154.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $307.00M derived: sum of 2 quarters · filed 2025-02-24 | $464.45M derived: sum of 3 quarters · filed 2025-02-24 | $611.81M 10-K · filed 2025-02-24 | |
| 2022-09-30 | $152.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $310.02M derived: sum of 2 quarters · filed 2023-11-02 | $457.38M 10-Q · filed 2023-11-02 | $657.38M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | $157.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $304.81M 10-Q · filed 2023-08-02 | $504.80M derived: sum of 3 quarters · filed 2024-02-26 | $757.38M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | $147.36M 10-Q · filed 2023-04-28 | $347.36M derived: sum of 2 quarters · filed 2024-02-26 | $599.93M derived: sum of 3 quarters · filed 2024-02-26 | ||
| 2021-12-31 | $200.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $452.57M derived: sum of 2 quarters · filed 2024-02-26 | $937.14M 10-K · filed 2024-02-26 | ||
| 2021-09-30 | $252.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $737.14M 10-Q · filed 2022-10-28 | |||
| 2021-06-30 | $484.57M 10-Q · filed 2022-08-04 | ||||
| 2020-12-31 | $529.66M 10-K · filed 2023-02-27 | ||||
| 2016-12-31 | $699.75M 10-K · filed 2017-02-27 | ||||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $58.91M 10-Q · filed 2016-08-08 | $89.22M derived: sum of 3 quarters · filed 2017-02-27 | $202.84M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2016-03-31 | $58.91M 10-Q · filed 2016-05-02 | $89.22M derived: sum of 2 quarters · filed 2017-02-27 | $202.84M derived: sum of 3 quarters · filed 2017-02-27 | $643.67M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2015-12-31 | $30.31M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $143.92M derived: sum of 2 quarters · filed 2017-02-27 | $584.75M derived: sum of 3 quarters · filed 2017-02-27 | $873.18M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $113.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $554.44M derived: sum of 2 quarters · filed 2016-08-08 | $842.87M 10-Q · filed 2015-11-02 | $900.97M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2015-06-30 | $440.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $729.26M 10-Q · filed 2016-08-08 | $787.36M derived: sum of 3 quarters · filed 2017-02-27 | $1.10B derived: sum of 4 quarters · filed 2017-02-27 | |
| 2015-03-31 | $288.43M 10-Q · filed 2016-05-02 | $346.53M derived: sum of 2 quarters · filed 2017-02-27 | $662.55M derived: sum of 3 quarters · filed 2017-02-27 | $711.16M derived: sum of 4 quarters · filed 2017-02-27 | |
| 2014-12-31 | $58.10M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $374.12M derived: sum of 2 quarters · filed 2017-02-27 | $422.73M derived: sum of 3 quarters · filed 2017-02-27 | $507.04M 10-K · filed 2017-02-27 | |
| 2014-09-30 | $316.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $364.63M derived: sum of 2 quarters · filed 2015-11-02 | $448.94M 10-Q · filed 2015-11-02 | $664.79M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | $48.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $132.92M 10-Q · filed 2015-08-05 | $348.77M derived: sum of 3 quarters · filed 2016-02-29 | $409.78M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | $84.31M 10-Q · filed 2015-05-05 | $300.16M derived: sum of 2 quarters · filed 2016-02-29 | $361.17M derived: sum of 3 quarters · filed 2016-02-29 | $410.58M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2013-12-31 | $215.85M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $276.86M derived: sum of 2 quarters · filed 2016-02-29 | $326.27M derived: sum of 3 quarters · filed 2016-02-29 | $395.04M 10-K · filed 2016-02-29 | |
| 2013-09-30 | $61.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $110.42M derived: sum of 2 quarters · filed 2014-10-28 | $179.19M 10-Q · filed 2014-10-28 | $284.54M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-06-30 | $49.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $118.18M 10-Q · filed 2014-07-31 | $223.53M derived: sum of 3 quarters · filed 2015-03-02 | $287.88M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-03-31 | $68.77M 10-Q · filed 2014-05-02 | $174.12M derived: sum of 2 quarters · filed 2015-03-02 | $238.47M derived: sum of 3 quarters · filed 2015-03-02 | $414.38M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2012-12-31 | $105.35M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $169.70M derived: sum of 2 quarters · filed 2015-03-02 | $345.61M derived: sum of 3 quarters · filed 2015-03-02 | $382.17M 10-K · filed 2015-03-02 | |
| 2012-09-30 | $64.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $240.25M derived: sum of 2 quarters · filed 2013-10-28 | $276.82M 10-Q · filed 2013-10-28 | $276.95M derived: sum of 4 quarters · filed 2014-02-26 | |
| 2012-06-30 | $175.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-29 | $212.47M 10-Q · filed 2013-07-29 | $212.60M derived: sum of 3 quarters · filed 2014-02-26 | $295.33M derived: sum of 4 quarters · filed 2014-02-26 | |
| 2012-03-31 | $36.56M 10-Q · filed 2013-04-29 | $36.69M derived: sum of 2 quarters · filed 2014-02-26 | $119.43M derived: sum of 3 quarters · filed 2014-02-26 | $177.78M derived: sum of 4 quarters · filed 2014-02-26 | |
| 2011-12-31 | $131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $82.86M derived: sum of 2 quarters · filed 2014-02-26 | $141.22M derived: sum of 3 quarters · filed 2014-02-26 | $215.43M 10-K · filed 2014-02-26 | |
| 2011-09-30 | $82.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-29 | $141.09M derived: sum of 2 quarters · filed 2012-10-29 | $215.30M 10-Q · filed 2012-10-29 | $288.07M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-06-30 | $58.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $132.56M 10-Q · filed 2012-08-02 | $205.34M derived: sum of 3 quarters · filed 2013-02-26 | $264.75M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-03-31 | $74.21M 10-Q · filed 2012-04-30 | $146.98M derived: sum of 2 quarters · filed 2013-02-26 | $206.40M derived: sum of 3 quarters · filed 2013-02-26 | $232.91M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2010-12-31 | $72.77M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $132.19M derived: sum of 2 quarters · filed 2013-02-26 | $158.70M derived: sum of 3 quarters · filed 2013-02-26 | $221.66M 10-K · filed 2013-02-26 | |
| 2010-09-30 | $59.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $85.93M derived: sum of 2 quarters · filed 2011-10-31 | $148.89M 10-Q · filed 2011-10-31 | $262.03M derived: sum of 4 quarters · filed 2012-02-22 | |
| 2010-06-30 | $26.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-01 | $89.47M 10-Q · filed 2011-08-01 | $202.62M derived: sum of 3 quarters · filed 2012-02-22 | $263.90M derived: sum of 4 quarters · filed 2012-02-22 | |
| 2010-03-31 | $62.96M 10-Q · filed 2011-04-29 | $176.10M derived: sum of 2 quarters · filed 2012-02-22 | $237.39M derived: sum of 3 quarters · filed 2012-02-22 | ||
| 2009-12-31 | $113.14M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $174.43M derived: sum of 2 quarters · filed 2012-02-22 | $445.55M 10-K · filed 2012-02-22 | $439.30M 10-K · filed 2011-02-24 | |
| 2009-09-30 | $61.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-29 | $332.41M 10-Q · filed 2010-10-29 | |||
| 2009-06-30 | $271.12M 10-Q · filed 2010-08-04 | ||||
| 2008-12-31 | $733.13M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |